Research Analysts Offer Predictions for CMPX FY2028 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Stock analysts at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for shares of Compass Therapeutics in a report issued on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.94 for the year, up from their prior forecast of $0.85. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03.

Several other analysts also recently commented on CMPX. Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 16th.

Compass Therapeutics Trading Down 5.9 %

Shares of CMPX opened at $1.59 on Thursday. The business’s fifty day simple moving average is $1.75 and its two-hundred day simple moving average is $1.42. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34. The company has a market cap of $218.77 million, a price-to-earnings ratio of -4.47 and a beta of 0.92.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Bleakley Financial Group LLC purchased a new position in shares of Compass Therapeutics in the 1st quarter worth $80,000. Renaissance Technologies LLC boosted its stake in shares of Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after buying an additional 70,200 shares during the last quarter. Rhumbline Advisers lifted its position in Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after purchasing an additional 12,315 shares in the last quarter. Vanguard Group Inc. lifted its position in Compass Therapeutics by 1.7% during the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after purchasing an additional 71,008 shares in the last quarter. Finally, Panagora Asset Management Inc. purchased a new position in Compass Therapeutics during the second quarter valued at $68,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.